In a retrospective study of 501 neonates with potential in utero substance exposure, the drug detection performance of a commercially available umbilical cord tissue toxicology test was evaluated against a commercially available gold standard meconium toxicology test. Drugs detected in paired meconium and umbilical cord tissue samples were often discordant. (J Pediatr 2019; 205:277-80) .
A ccording to the 2016 National Survey on Drug Use and Health, nearly 20% of US pregnant women aged 15-44 years are estimated to have used alcohol, tobacco, or other illicit drugs during their pregnancy. 1 Accurate assessment of substance exposure has implications for both the infant and mother. [2] [3] [4] [5] The American College of Obstetrics and Gynecology and the American Academy of Pediatrics recommend that screening of substance use in pregnancy be universal to avoid bias and be done using a standardized screening tool (eg, parents, partners, past, and pregnancy [4Ps] or car, relax, alone, forget, friends, and trouble [CRAFFT]). 5, 6 Suspected substance use in pregnancy is commonly confirmed using toxicology tests on specimens from the infant. 7, 8 Meconium, the stool produced by the neonate during gestation, has a long window of drug detection and is generally considered the gold standard test [7] [8] [9] [10] ; however, collection can be challenging, and meconium is not always available in sufficient quantities. [11] [12] [13] Umbilical cord tissue has been proposed as an alternative to meconium because it is readily available in large quantities at the time of birth [14] [15] [16] [17] ; however, the window of drug detection in umbilical cord tissue is generally considered shorter than that in meconium. 7, 9 Most previous studies assessing the comparability of umbilical cord tissue and meconium have involved small cohorts of paired samples in which few subjects tested positive for drugs 15, [18] [19] [20] [21] or large cohorts in which samples were not paired. 17 Larger cohorts with paired samples have been examined. 9, 14, 22 Owing to a combination of biochemical differences in drug or metabolite deposition and accumulation in umbilical cord tissue and meconium and differences in cohort size, frequency of drug abuse in the test population, drugs and metabolites included in the test panel, and test methodology, the literature is conflicted as to whether umbilical cord tissue is equivalent to meconium for confirming in utero substance exposure, and both tests are currently used in practice.
To evaluate the equivalence of the umbilical cord tissue and meconium toxicology tests in use at our institution for confirmation of in utero substance exposure, we examined results from a cohort of 501 neonates that underwent both umbilical cord tissue and meconium toxicology testing performed by a national reference laboratory.
Methods
This retrospective cohort study comprised a convenience sample of 501 infants who underwent screening for drug exposure using both meconium and umbilical cord tissue at the Monroe Carell Jr Children's Hospital at Vanderbilt between October 1, 2013, and February 1, 2016. Subjects were excluded from analysis for a specific drug group if toxicology results were not available in both umbilical cord tissue and meconium. This study was reviewed and approved by the Vanderbilt University Medical Center's Institutional Review Board (IRB172002, 160434, and 150839). The study population includes partial data from 217 subjects reported previously reported 22 along with an additional 284 subjects.
Toxicology Testing
All provider-ordered toxicology testing was performed by a national reference laboratory (Associated Regional and University Pathologists, Salt Lake City, Utah) using a combination of immunoassay and chromatography-mass spectrometry techniques. 18, [23] [24] [25] [26] [27] Both the umbilical cord tissue and meconium tests were commercially available but were performed using different methodologies and had different limits of drug detection. In addition, the umbilical cord tissue and meconium tests detected different drugs, and for the purpose of this study, drugs that were available only in either the umbilical cord tissue panel or the meconium panel were excluded from analysis. The drugs analyzed in this study and the limits of detection in umbilical cord tissue and meconium are listed in Table I .
Data Collection
Results for umbilical cord tissue and meconium toxicology testing were collected retrospectively from the hospital's laboratory information system (Millennium; Cerner, North Kansas City, Missouri). Subjects' demographic and length of stay data were collected retrospectively from the laboratory billing system (HealthQuest; McKesson, San Francisco, California). Additional clinical information was collected through medical record review.
Statistical Analyses
We included 38 individual drugs from 8 groups in our analysis (Table I) . Meconium results were defined as the gold standard for drug presence, and measures of diagnostic utility were calculated for each drug group in umbilical cord tissue. Sensitivity, specificity, agreement, positive predictive value, negative predictive value, prevalence, and Cohen k (k = po -pe/1 -p e, where po is the observed proportionate agreement and pe is the probability of random agreement) were calculated using EP Evaluator software (Data Innovations, Burlington, Vermont). A k value of 100% indicates perfect agreement, and a value of 0% indicates random agreement. For the purposes of this analysis, a k value of ≥75% was deemed acceptable. 22 The 95% CIs were calculated with the Wilson score method using EP Evaluator.
Results
A total of 501 subjects were included in this single-center study. The study population was predominantly Caucasian (69.9%). More than 37% of the subjects had a neonatal intensive care unit stay, with a median length of stay of 15 days. The results of umbilical cord tissue and meconium toxicology tests were compared by drug group (Tables I and II) . Although the overall prevalence of drugs in umbilical cord tissue and meconium was similar for many drug groups, umbilical cord tissue had slightly higher prevalences of amphetamines, barbiturates, and benzodiazepines. The overall agreement between umbilical cord tissue and meconium ranged from 80% to 100%. Cohen k, which accounts for agreement due to chance, ranged from 40% to 88%. Only 2 drug groups, amphetamines and methadone, had acceptable k values of ≥75%. The sensitivity of umbilical cord tissue ranged from 41% for cannabinoids (95% CI, 33.3%-49.6%) to 100% for barbiturates (95% CI, 34.2%-100.0%). The sensitivity of umbilical cord tissue for opioids ranged from 53% for other opioids (95% CI, 43.9%-62.3%) to 75% for methadone (95% CI, 50.5%-89.8%) ( Table II) .
Discussion
Our study builds on several previous smaller studies that used paired samples to assess confirmation of in utero substance exposure using umbilical cord tissue and meconium testing. 14, 15, 18, 22 Our results demonstrate variable detection of drugs between paired umbilical cord tissue and meconium samples, as evidenced by lack of concordance and relatively low k values (Table II) . Our findings support other studies demonstrating that paired umbilical cord tissue and meconium results are often discordant. 9, 14, 22 Differences in analytical detection limits of the tests may play a role in some of the discrepancies, as may administration of drugs close to or during labor. In addition, commercially available umbilical cord tissue testing might not include drug metabolites that preferentially accumulate in umbilical cord tissue, and thus may contribute to false-negative umbilical cord tissue results.
Our study has some limitations that merit mention. The drugs detected in study subjects are representative of use patterns observed in our setting, which might not be generalizable to other settings with different drug prevalences. The umbilical cord tissue and meconium tests rely on different but related analytical principles. Both tests underwent improvements during the study period. Because there is no Food and Drug Administration-approved toxicology test for meconium or umbilical cord tissue, each laboratory's tests will be unique, and the tests used in this study might not be equivalent to tests performed by other laboratories. Both tests that we used are commercially available, offer analytes and detection limits similar to tests offered by other commercial laboratories, and have been used in a number of previous studies. 15, 17, 22 The choice of meconium or umbilical cord tissue testing should be based on a number of factors, some of which are scientific (eg, window of detection) and some of which are practical (eg, specimen availability). Both umbilical cord tissue and meconium have a place in the confirmation of in utero substance exposure, provided that those interpreting the results are aware that umbilical cord tissue and meconium might not produce equivalent results. 
